Pallarés J et al. - In a study to assess the immunohistochemical expression of RASSF1A in normal endometrium and endometrial carcinoma, and correlate its expression with K-RAS mutations, presence of microsatellite instability, RASSF1A promoter methylation, and clinicopathological data, it was determined that reduced expression of RASSF1A may play a role in endometrial carcinogenesis by controlling cell proliferation and apoptosis through the MAPK-signaling pathway Methods
RASSF1A immunostaining was evaluated in 1 tissue microarray constructed from 80 paraffin-embedded samples of normal endometrium, and 2 tissue microarrays constructed with a total of 157 endometrial carcinomas
RASSF1A immunostaining was correlated with cell proliferation (Ki67), Cyclin D1 expression, and clinicopathological data
Promoter methylation of RASSF1A was assessed by methylation-specific PCR
Results
RASSF1A immunostaining was variable during the menstrual cycle in normal endometrium
RASSF1A expression was significantly reduced in 48% of endometrial carcinomas, particularly in tumors exhibiting microsatellite instability
RASSF1A-promoter methylation was very frequent in endometrial carcinoma, and was frequently associated with reduced expression of RASSF1A
RASSF1A-promoter hypermethylation was common in advanced-stage endometrial carcinoma
See all
